<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126190">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02039674</url>
  </required_header>
  <id_info>
    <org_study_id>3475-021</org_study_id>
    <nct_id>NCT02039674</nct_id>
  </id_info>
  <brief_title>A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)</brief_title>
  <official_title>A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety, tolerability, and efficacy of
      pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants
      with unresectable or metastatic non-small cell lung cancer (NSCLC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Part II, Cohort G: Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II, Cohort G: Objective Response Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II, Cohort H: Overall Response Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I, All Cohorts: the recommended Phase II dose for pembrolizumab in combination with chemotherapy or immunotherapy</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Non-small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Part I, Cohort A (Pembro + Paclitaxel [Pa] + Carboplatin [C])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pembrolizumab (2 or 10 mg/kg) + paclitaxel (200 mg/m^2) + carboplatin (6 mg/mL/minute)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pembrolizumab (2 or 10 mg/kg) + paclitaxel (200 mg/m^2) + carboplatin (6 mg/mL/minute) + bevacizumab (15 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, Cohort C (Pembro + Pemetrexed [Pe] + C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pembrolizumab (2 or 10 mg/kg) + Pemetrexed (500 mgm^2) + Carboplatin (5 mg/mL/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, Cohort D (Pembro + Ipilimumab [I])</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pembrolizumab ( (2 or 10 mg/kg) + Ipilimumab (0.3, 1, or 3 mg/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, Cohort E (Pembro + Erlotinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pembrolizumab (2 or 10 mg/kg) + Erlotinib (150 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, Cohort F (Pembro + Gefitinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pembrolizumab (2 or 10 mg/kg) + Gefitinib (250 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II, Cohort G (Pembro + chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort G1: selected dose of pembrolizumab and chemotherapies from cohorts A,B, and C. Cohort G2: there may be an optional Cohort G2, depending on the results of G1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II, Cohort H (Pembro + I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>selected dose of pembrolizumab and ipilimumab from cohort D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>intravenously (IV) every 3 weeks (Q3W) on Day 1 of each cycle prior to chemo/immunotherapy</description>
    <arm_group_label>Part I, Cohort A (Pembro + Paclitaxel [Pa] + Carboplatin [C])</arm_group_label>
    <arm_group_label>Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])</arm_group_label>
    <arm_group_label>Part I, Cohort C (Pembro + Pemetrexed [Pe] + C)</arm_group_label>
    <arm_group_label>Part I, Cohort D (Pembro + Ipilimumab [I])</arm_group_label>
    <arm_group_label>Part I, Cohort E (Pembro + Erlotinib)</arm_group_label>
    <arm_group_label>Part I, Cohort F (Pembro + Gefitinib)</arm_group_label>
    <arm_group_label>Part II, Cohort G (Pembro + chemotherapy)</arm_group_label>
    <arm_group_label>Part II, Cohort H (Pembro + I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>IV Q3W on Day 1 of each cycle</description>
    <arm_group_label>Part I, Cohort A (Pembro + Paclitaxel [Pa] + Carboplatin [C])</arm_group_label>
    <arm_group_label>Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])</arm_group_label>
    <arm_group_label>Part II, Cohort G (Pembro + chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>IV Q3W on Day 1 of each cycle</description>
    <arm_group_label>Part I, Cohort A (Pembro + Paclitaxel [Pa] + Carboplatin [C])</arm_group_label>
    <arm_group_label>Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])</arm_group_label>
    <arm_group_label>Part I, Cohort C (Pembro + Pemetrexed [Pe] + C)</arm_group_label>
    <arm_group_label>Part II, Cohort G (Pembro + chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV Q3W on Day 1 of each cycle</description>
    <arm_group_label>Part I, Cohort B (Pembro + Pa + C+ Bevacizumab [B])</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>IV Q3W on Day 1 of each cycle</description>
    <arm_group_label>Part I, Cohort C (Pembro + Pemetrexed [Pe] + C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>IV Q3W on Day 1 of each cycle</description>
    <arm_group_label>Part I, Cohort D (Pembro + Ipilimumab [I])</arm_group_label>
    <arm_group_label>Part II, Cohort H (Pembro + I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Orally (po) daily (QD)</description>
    <arm_group_label>Part I, Cohort E (Pembro + Erlotinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>po QD</description>
    <arm_group_label>Part I, Cohort F (Pembro + Gefitinib)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage IIIb/IV NSCLC

          -  at least one radiographically measurable lesion

          -  performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Status

          -  Females are not pregnant nor of child-bearing potential

          -  if of childbearing potential, females must be willing to use two adequate barrier
             methods throughout the study

          -  males with a female partner(s) of child-bearing potential must agree to use two
             adequate barrier methods throughout the trial

        Exclusion Criteria:

          -  currently participating or has participated in a study of an investigational agent or
             using an investigational device within 30 days of administration of pembrolizumab

          -  expected to require any other form of antineoplastic therapy while on study

          -  is on chronic systemic steroid therapy or on any other form of immunosuppressive
             medication

          -  has received a live-virus vaccination within 30 days of planned treatment start

          -  history of diverticulitis, intra-abdominal abscess, gastrointestinal (GI)
             obstruction, abdominal carcinomatosis which are known risks factors for bowel
             perforation

          -  history of a hematologic malignancy, primary brain tumor or sarcoma, or of another
             primary solid tumor, unless the participant has undergone potentially curative
             therapy with no evidence of that disease for 5 years

          -  active central nervous system (CNS) metastases and/or carcinomatous meningitis

          -  severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)

          -  active autoimmune disease or a documented history of autoimmune disease or syndrome
             that requires systemic steroids or immunosuppressive agents

          -  prior treatment with any other anti-programmed cell death protein-1 (anti-PD-1), or
             PD Ligand-1 (PD-L1) or PD Ligand-2 (PD-L2) agent or an antibody targeting other
             immuno-regulatory receptors or mechanisms

          -  active infection requiring therapy

          -  history of Human Immunodeficiency Virus (HIV)

          -  active Hepatitis B or C.

          -  symptomatic ascites or pleural effusion

          -  pneumonitis that has required a course of oral steroids to assist with recovery, or a
             history of interstitial lung disease

          -  pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the study

          -  psychiatric disorders and substance (drug/alcohol) abuse
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0005)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0013)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0007)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0003)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>January 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-1</keyword>
  <keyword>PD1</keyword>
  <keyword>Programmed Cell Death-1</keyword>
  <keyword>Programmed Cell Death 1</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
